Pharmaceutical

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of…

12 months ago

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major…

12 months ago

TOMI Announces Preliminary Second Quarter Revenue Growth of 90%

FREDERICK, Md., July 24, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

12 months ago

Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty…

12 months ago

Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling

Interim Data Analysis anticipated in Early 2024MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical…

12 months ago

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ETCORAL GABLES, Fla., July…

12 months ago

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon…

12 months ago

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase…

12 months ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition…

12 months ago

ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering

WESTON, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical…

12 months ago